Results 1 to 10 of about 3,733,624 (286)
Downstream processing of bioproducts [PDF]
Sonja Berensmeier
doaj +5 more sources
Advances in Downstream Processing of Monoclonal Antibodies [PDF]
Although mAbs have great therapeutic potential, their use in medicine is currently limited by the high cost of their manufacturing. Significant developments in upstream processing technologies have caused downstream processing (DSP) to become the ...
Michał Kołodziej, Dorota Antos
doaj +2 more sources
Ionic-liquid-based approaches to improve biopharmaceuticals downstream processing and formulation [PDF]
The emergence of biopharmaceuticals, including proteins, nucleic acids, peptides, and vaccines, revolutionized the medical field, contributing to significant advances in the prophylaxis and treatment of chronic and life-threatening diseases.
Catarina Almeida +4 more
doaj +2 more sources
Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies [PDF]
Allan Matte
exaly +2 more sources
The Global Diabetes Compact was launched by the World Health Organization in April 2021 with one of its important goals to increase the accessibility and affordability of life-saving medicine—insulin.
Yin Yin Siew, Wei Zhang
doaj +1 more source
Effective flow-through polishing strategies for knob-into-hole bispecific antibodies
Bispecific antibodies (bsAbs), though possessing great therapeutic potential, are extremely challenging to obtain at high purity within a limited number of scalable downstream processing steps.
Serene W. Chen +4 more
doaj +1 more source
Bispecific antibodies (bsAbs) are therapeutically promising due to their ability to bind to two different antigens. However, the bsAb byproducts and impurities, including mispaired homodimers, half-antibodies, light chain mispairings, antibody fragments ...
Serene W. Chen +4 more
doaj +1 more source
Tandem single-chain variable fragment (scFv) bispecific antibodies (bsAb) are one of the most promising bsAb formats reported thus far. Yet, because of their increased aggregation propensity, high impurity content due to low expression level, smaller ...
Serene W. Chen +3 more
doaj +1 more source
The aim of this work was to apply a modeling integrated optimisation approach for a complex, highly nonlinear system for an extracellular lipase extraction process. The model was developed using mutation, crossover and selection variables of Differential
Vijay Kumar Garlapati +2 more
doaj +1 more source
Bispecific antibody (bsAb), a novel therapeutic modality, provides excellent treatment efficacy, yet poses numerous challenges to downstream process development, which are mainly due to the intricate diversity of bsAb structures and impurity profiles ...
Nattha Ingavat +10 more
doaj +1 more source

